NASDAQ: UNCY

U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), granting Lee’s exclusive rights to develop, market, and commercialize Renazorb (lanthanum dioxycarbonate) in mainland China, Hong Kong, and other Asian markets. Licensing TermsUnder the agreement, Unicycive will receive an upfront…